#1 Clinical Trials Search in Europe

Pemetrexed Diacid Monohydrate

Pemetrexed Diacid Monohydrate is a drug being studied in clinical trials for the treatment of metastatic non-small cell lung cancer (NSCLC). This article explores its use in combination with other therapies and its potential benefits for patients with this serious condition. We’ll discuss the ongoing research, eligibility criteria, and what patients can expect from participating in these trials.

Table of Contents

What is Pemetrexed Diacid Monohydrate?

Pemetrexed Diacid Monohydrate is an active substance used in cancer treatment. It belongs to a class of drugs known as antineoplastic agents, which are used to treat various types of cancer[1]. The medication is marketed under different brand names, including Albotiva, which is available as a 25 mg/ml concentrate for solution for infusion[1].

Medical Conditions Treated

Pemetrexed Diacid Monohydrate is primarily used to treat non-small cell lung cancer (NSCLC), particularly in its advanced or metastatic stages. It can be used for both nonsquamous and squamous types of NSCLC[1]. Metastatic cancer refers to cancer that has spread from its original site to other parts of the body.

How is it Administered?

Pemetrexed Diacid Monohydrate is administered through intravenous (IV) use. This means it is given directly into a vein. The medication comes as a concentrate that is diluted to create a solution for injection or infusion[1]. The infusion is typically given by healthcare professionals in a clinical setting.

Dosage Information

The dosage of Pemetrexed Diacid Monohydrate is typically calculated based on the patient’s body surface area. The maximum daily dose is usually 500 mg/m² (milligrams per square meter of body surface area). The total maximum dose over the course of treatment can be up to 17,500 mg/m²[1]. The treatment period can last up to 24 months, depending on the patient’s response and tolerance to the medication.

Current Clinical Trial

A phase 3 clinical trial (POD1UM-304) is currently being conducted to evaluate the effectiveness of combining Pemetrexed Diacid Monohydrate with other treatments for metastatic NSCLC. The trial aims to compare the overall survival (OS) of patients receiving a combination of INCMGA00012 (an investigational drug) and chemotherapy versus those receiving placebo and chemotherapy[1].

Key points about the trial include:

  • It’s a randomized, double-blind study, meaning neither the patients nor the researchers know who is receiving which treatment.
  • The trial focuses on first-line treatment for metastatic squamous and nonsquamous NSCLC.
  • Secondary objectives include comparing progression-free survival (PFS), objective response rate (ORR), and duration of response (DOR) between the two treatment groups[1].

Potential Side Effects and Precautions

As with any medication, Pemetrexed Diacid Monohydrate may cause side effects. While the specific side effects are not detailed in the provided information, patients should be aware of the following precautions:

  • Patients with a history of severe hypersensitivity reactions to monoclonal antibodies or known sensitivity to pemetrexed should not receive this treatment[1].
  • Patients must be able to take folic acid and vitamin B12 supplementation[1].
  • Those with active infections, autoimmune diseases, or who have recently received live vaccines may not be suitable candidates for this treatment[1].
  • Patients with a history of interstitial lung disease or active pneumonitis should not receive this medication[1].

It’s crucial for patients to discuss their full medical history and any concerns with their healthcare provider before starting treatment with Pemetrexed Diacid Monohydrate.

Aspect Details
Drug Name Pemetrexed Diacid Monohydrate (Albotiva)
Condition Studied Metastatic non-small cell lung cancer (NSCLC)
Trial Phase Phase 3
Administration Intravenous use
Dosage 500 mg/m² (maximum daily dose)
Treatment Duration Up to 24 months
Main Objectives Compare overall survival, progression-free survival, and objective response rate
Key Eligibility Criteria Adults with confirmed metastatic NSCLC, no prior systemic treatment for advanced disease
Safety Monitoring Adverse events, discontinuations due to adverse events

FAQ

  • What is Pemetrexed Diacid Monohydrate? Pemetrexed Diacid Monohydrate is a chemotherapy drug used in the treatment of non-small cell lung cancer. It works by interfering with the growth of cancer cells.
  • How is Pemetrexed Diacid Monohydrate administered in clinical trials? In the clinical trial, Pemetrexed Diacid Monohydrate is administered intravenously (through a vein) as part of a combination therapy with other drugs.
  • Who is eligible for the clinical trial using Pemetrexed Diacid Monohydrate? Eligible participants are adults with histologically or cytologically confirmed metastatic non-small cell lung cancer (either nonsquamous or squamous) who have not received prior systemic treatment for their advanced disease.
  • What are the main goals of the clinical trial? The main goals of the trial are to compare the overall survival, progression-free survival, and response rates of patients receiving the combination therapy including Pemetrexed Diacid Monohydrate versus those receiving standard chemotherapy.
  • Are there any specific precautions for participants in the trial? Yes, participants must be willing to take folic acid and vitamin B12 supplementation, avoid pregnancy or fathering children during the study, and meet certain health criteria. They should also discuss COVID-19 vaccination with their doctor before entering the study.

Ongoing Clinical Trials on Pemetrexed Diacid Monohydrate

  • Study on the Effectiveness of Retifanlimab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated drugs:
    Bulgaria Czechia

Glossary

  • Non-Small Cell Lung Cancer (NSCLC): A type of lung cancer that includes several subtypes, such as adenocarcinoma and squamous cell carcinoma. It is the most common form of lung cancer.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Chemotherapy: A type of cancer treatment that uses drugs to destroy cancer cells.
  • Intravenous (IV): Administered directly into a vein.
  • Overall Survival (OS): The length of time from the start of treatment until death from any cause.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease without it getting worse.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Adverse Events (AEs): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • ECOG Performance Status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-retifanlimab-with-chemotherapy-for-patients-with-metastatic-non-small-cell-lung-cancer/